Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$28.19 USD
+0.54 (1.95%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $28.21 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.19 USD
+0.54 (1.95%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $28.21 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug
by Zacks Equity Research
Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.
Ryan Specialty Group (RYAN) Meets Q3 Earnings Estimates
by Zacks Equity Research
Ryan Specialty (RYAN) delivered earnings and revenue surprises of 0% and 0.20%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Houlihan Lokey (HLI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Houlihan Lokey (HLI) delivered earnings and revenue surprises of 11% and 4.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Alerus (ALRS) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Alerus (ALRS) delivered earnings and revenue surprises of 32.35% and 3.83%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
RPRX vs. BAM: Which Stock Is the Better Value Option?
by Zacks Equity Research
RPRX vs. BAM: Which Stock Is the Better Value Option?
Compared to Estimates, Royalty Pharma (RPRX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Royalty Pharma (RPRX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.41% and 1.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Royalty Pharma (RPRX) Might Surprise This Earnings Season
by Zacks Equity Research
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Trupanion (TRUP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Trupanion (TRUP) delivered earnings and revenue surprises of 21.43% and 3.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
PJT Partners (PJT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
PJT Partners (PJT) delivered earnings and revenue surprises of 54.69% and 41.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Implied Volatility Surging for Royalty Pharma (RPRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Royalty Pharma (RPRX) stock based on the movements in the options market lately.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Royalty Pharma (RPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Royalty Pharma (RPRX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 21.21% and 23.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Royalty Pharma (RPRX) Ahead of Earnings?
by Zacks Equity Research
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Owl Rock Capital Corporation (ORCC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Owl Rock Capital Corporation (ORCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MVB Financial (MVBF) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
MVB Financial (MVBF) delivered earnings and revenue surprises of -65.52% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Is PRA Group (PRAA) Down 10.4% Since Last Earnings Report?
by Zacks Equity Research
PRA Group (PRAA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GBOOY vs. RPRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
GBOOY vs. RPRX: Which Stock Is the Better Value Option?
GBOOY or RPRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GBOOY vs. RPRX: Which Stock Is the Better Value Option?